滋养层细胞表面抗原 2 (Trop2) 在一系列实体瘤中过度表达，并参与多种致癌信号通路，使其成为有吸引力的治疗靶点。在过去的十年中，各种 Trop2 靶向疗法的快速发展，特别是抗体药物偶联物 (ADC) 的出现，彻底改变了治疗意见有限（例如三阴性）的 Trop2 阳性肿瘤患者的治疗结果乳腺癌（TNBC）。这篇综述全面总结了 Trop2 靶向疗法的进展，包括 ADC、抗体、多特异性药物、免疫疗法、癌症疫苗和小分子抑制剂，并深入讨论了它们的设计、作用机制 (MOA) 和限制。此外，我们强调这些新兴Trop2靶向药物的临床研究进展，重点关注其临床应用和对肿瘤的治疗效果。此外，我们提出了未来的研究方向，例如增强对Trop2结构和生物学的理解，探索最佳组合策略，以及基于Trop2测试方法定制精准治疗。©作者。

Trophoblast cell surface antigen 2 (Trop2) is overexpressed in a range of solid tumors and participants in multiple oncogenic signaling pathways, making it an attractive therapeutic target. In the past decade, the rapid development of various Trop2-targeted therapies, notably marked by the advent of the antibody-drug conjugate (ADC), revolutionized the outcome for patients facing Trop2-positive tumors with limited treatment opinions, such as triple-negative breast cancer (TNBC). This review provides a comprehensive summary of advances in Trop2-targeted therapies, including ADCs, antibodies, multispecific agents, immunotherapy, cancer vaccines, and small molecular inhibitors, along with in-depth discussions on their designs, mechanisms of action (MOAs), and limitations. Additionally, we emphasize the clinical research progress of these emerging Trop2-targeted agents, focusing on their clinical application and therapeutic efficacy against tumors. Furthermore, we propose directions for future research, such as enhancing our understanding of Trop2's structure and biology, exploring the best combination strategies, and tailoring precision treatment based on Trop2 testing methodologies.© The author(s).